Results From the First Randomised Study in Multicentric Castleman's Disease, a Rare Lymphoproliferative Disorder: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Siltuximab, an Anti -Interleukin-6 Monoclonal Antibody